Given the emergence of novel pharmacological diabetes therapies, such as SGLT2 inhibitors, our findings support future studies examining the benefit of SGLT2 inhibitors earlier in the dysglycemia spectrum for the prevention of HF. The gene discussed is SLC5A2; the disease is hydrops fetalis.